Compare CELC & MAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELC | MAT |
|---|---|---|
| Founded | 2011 | 1945 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.2B |
| IPO Year | 2017 | 1994 |
| Metric | CELC | MAT |
|---|---|---|
| Price | $86.82 | $14.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $112.56 | $20.90 |
| AVG Volume (30 Days) | 1.1M | ★ 4.3M |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $5,347,623,000.00 |
| Revenue This Year | N/A | $5.92 |
| Revenue Next Year | $720.19 | $5.08 |
| P/E Ratio | ★ N/A | $106.25 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.42 | $12.73 |
| 52 Week High | $151.02 | $22.48 |
| Indicator | CELC | MAT |
|---|---|---|
| Relative Strength Index (RSI) | 45.01 | 56.01 |
| Support Level | $82.48 | $14.11 |
| Resistance Level | $95.59 | $15.33 |
| Average True Range (ATR) | 4.57 | 0.47 |
| MACD | 0.54 | -0.01 |
| Stochastic Oscillator | 58.30 | 49.32 |
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Mattel manufactures and markets toy products that are sold to its wholesale partners and direct to retail customers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, hand-held and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Nearly 60% of its net sales were generated from North America in 2025, with the remainder stemming from international markets.